EMERYVILLE, Calif., Nov. 13, 2023 /PRNewswire/ — Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today unveiled new clinical data at the 2023 American Heart Association Scientific Sessions. This data demonstrated the real-world clinical efficacy of Eko’s AI-enabled SENSORA™ Platform to quickly and accurately detect structural murmurs associated with valvular heart disease. Valvular heart disease (VHD) is a medical condition present in over 50% of adults over the age of 65. VHD can lead to heart failure, stroke, and death, and if left undetected and untreated, can progress from moderate to severe within one year. Unfortunately, symptoms of VHD are frequently nonspecific, and more than half of patients with moderate to severe disease are asymptomatic, making VHD challenging to detect with conventional medical practice.
Read more here.